Definition, Diagnostic Criteria & Classification

Question	Answer
1. Detail the Modified Camitta Criteria for Severe Aplastic Anemia (SAA) and Very Severe Aplastic Anemia (vSAA).	Requires Hypocellular Bone Marrow with cellularity $<25\%$ (or $25-50\%$ with $<30\%$ residual hematopoietic cells), PLUS at least two of the following three peripheral blood cytopenias: 1) Absolute Neutrophil Count (ANC): $<500/\mu\text{L}$ ($<0.5 \times 10^9/\text{L}$). 2) Platelet Count: $<20,000/\mu\text{L}$ ($<20 \times 10^9/\text{L}$). 3) Absolute Reticulocyte Count (ARC): $<60,000/\mu\text{L}$ (or reticulocytes $<1.0\%$ or $<20,000/\mu\text{L}$ by automated methods). - Very Severe Aplastic Anemia (vSAA): Fulfills all criteria of SAA, EXCEPT that the ANC is $<200/\mu\text{L}$ ($<0.2 \times 10^9/\text{L}$).
2. What is Fanconi Anemia (FA), and what is its genetic basis?	- Definition: The most prevalent inherited bone marrow failure syndrome (IBMFS), characterized by physical dysmorphisms, progressive bone marrow aplasia (typically manifesting between 5 and 10 years of age), and high susceptibility to acute myeloid leukemia (AML) and squamous cell carcinomas. - Genetics: Primarily Autosomal Recessive (rarely X-linked in FANCB or autosomal dominant in FANCR/RAD51). Caused by mutations in genes encoding the FA/BRCA DNA repair pathway (most commonly FANCA in 60-70%, FANCC, FANCG), which repairs DNA interstrand cross-links during replication.
3. What are the classical physical dysmorphic features of Fanconi Anemia?	1) Radial Ray & Skeletal Anomalies (in 50-70%): Hypoplastic, bifid, or absent thumbs; floating thumb ('pouce flottant'); absent or hypoplastic radius; short stature. 2) Cutaneous Findings: Generalized mottled hyperpigmentation and multiple Café-au-lait macules ($\ge 3$, diameter $>1.5\text{ cm}$). 3) Craniofacial & Ocular: Microcephaly, microphthalmia, epicanthal folds, and triangular facies. 4) Renal & Urogenital: Horseshoe kidney, pelvic/ectopic kidney, renal agenesis; cryptorchidism, hypospadias. 5) Otological: Conductive hearing loss with external auditory canal stenosis. - VIVA TRAP: Up to $25-30\%$ of Fanconi anemia patients have ZERO physical dysmorphic features and present with isolated aplastic anemia!
4. Detail the Gold Standard Diagnostic Test for Fanconi Anemia.	- The Diepoxybutane (DEB) / Mitomycin C (MMC) Chromosomal Breakage Analysis: - Peripheral blood T-lymphocytes are cultured in vitro with DNA cross-linking clastogenic agents (DEB or MMC). - Normal lymphocytes repair cross-links without structural disruption. - Cells from Fanconi anemia patients exhibit a pathognomonic high frequency of chromosomal breaks, gaps, chromatid exchanges, and multiradial figures (triradials and quadriradials). - Flow cytometric cell cycle analysis demonstrates arrest in the $G_2/M$ phase.
5. VIVA TRAP: Why are organomegaly (hepatosplenomegaly) and lymphadenopathy ABSENT in pure Aplastic Anemia?	In aplastic anemia, the underlying pathology is primary stem cell destruction / exhaustion yielding an 'empty', hypocellular fatty bone marrow. There is no clonal infiltration, no leukemic proliferation, no extramedullary hematopoiesis, and no active inflammatory reticuloendothelial uptake. Examiner Rule: Finding significant hepatosplenomegaly or generalized lymphadenopathy in a child with pancytopenia strongly excludes pure aplastic anemia and points toward acute leukemia, lymphoma, myelofibrosis, Gaucher disease, or hemophagocytic lymphohistiocytosis (HLH)!

Pathophysiology & Therapeutics

Question	Answer
6. Contrast the first-line therapeutic algorithm for SAA with vs without an HLA-Matched Sibling Donor (MSD).	- Scenario A: Patient with SAA AND an HLA-Matched Sibling Donor (MSD): - First-Line Therapy is UPFRONT Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). - Curative in $>85-90\%$, restoring normal donor hematopoiesis and eliminating late clonal evolution. - Scenario B: Patient with SAA WITHOUT an HLA-Matched Sibling Donor: - First-Line Therapy is Triple Immunosuppressive Therapy (Triple IST): 1) Horse Anti-Thymocyte Globulin (Horse ATG - ATGAM): $40\text{ mg/kg/day}$ IV daily x 4 days. 2) Cyclosporine A (CsA): $5\text{ mg/kg/day}$ orally divided q12h (target trough $150-250\text{ ng/mL}$) for 12-24 months. 3) Eltrombopag (TPO-RA): $2.5\text{ mg/kg/day}$ orally starting Day 14. (Triple IST achieves response rates $>80\%$).
7. VIVA TRAP: Why is Horse ATG significantly superior to Rabbit ATG in treatment-naive Severe Aplastic Anemia?	High-quality prospective randomized trials (NIH and EBMT trials) proved that Horse ATG yields a dramatically higher hematological response rate ($68\%$ vs $37\%$) and superior overall survival compared to Rabbit ATG in treatment-naive aplastic anemia! Rabbit ATG causes prolonged, excessive T-cell depletion and higher opportunistic infectious mortality. Rabbit ATG is reserved strictly for patients who relapse or fail initial Horse ATG therapy!
8. Detail the strict Transfusion Rules in a patient who is a prospective HSCT candidate.	1) Leukoreduction & Irradiation: Transfuse strictly leukodepleted, irradiated packed red cells and platelets to prevent HLA alloimmunization, CMV transmission, and transfusion-associated graft-versus-host disease (TA-GVHD). 2) Prohibition of Family Donors (CRITICAL VIVA TRAP): NEVER use directed blood products from parents, siblings, or blood relatives! Transfusion from family members exposes the recipient to minor histocompatibility antigens shared with the prospective bone marrow donor, leading to severe immunological sensitization and catastrophic primary graft rejection during transplantation!

VIVA TRAPs & Counter-Questions

Question

Answer

9. VIVA TRAP: Why is standard Myeloablative Conditioning (high-dose Cyclophosphamide 200 mg/kg) FATAL in Fanconi Anemia HSCT?

Fanconi anemia cells have an intrinsic, constitutional defect in DNA repair. Administering standard high-dose myeloablative chemotherapy or full-dose total body irradiation results in massive, fatal endothelial, pulmonary, and mucosal toxicity!
Conditioning Protocol in Fanconi Anemia: Must utilize Reduced-Intensity Conditioning (RIC) with low-dose Cyclophosphamide ($40-60\text{ mg/kg}$) + Fludarabine ($120-150\text{ mg/m}^2$) + Anti-Thymocyte Globulin.

10. Counter-Question Chain: "A 6-year-old child with severe aplastic anemia has no sibling donor. What medical therapy can be given if IST is delayed or contraindicated in Fanconi Anemia?"

- Synthetic Androgens (Oxymetholone): $1.0\text{ to } 2.0\text{ mg/kg/day}$ orally.
- Mechanism: Stimulates erythropoietin gene transcription and expands primitive hematopoietic progenitors.
- Response: Induces erythroid and platelet responses in $50-60\%$ of Fanconi patients.
- Mandatory Surveillance: Every 6 months, screen liver enzymes and perform hepatic ultrasonography to detect drug-induced cholestatic jaundice, peliosis hepatis, and hepatic adenomas (which can transform into hepatocellular carcinoma).